Trial · NCT07883512
EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)
NCT07883512, Phase 2, Not yet recruiting, Virginia Commonwealth University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction). Trials, record NCT07883512. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883512
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)
- NCT number
- NCT07883512
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Virginia Commonwealth University
- Conditions
- Breast Cancer, Supportive Care in Cancer
- Interventions
- Empagliflozin
- First posted
- 2026-10-20
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the feasibility of investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including participant recruitment | Day 1 (Estimated enrollment period of 6 months) | The number of participants enrolled |
| Primary | Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including medication adherence | 3-month follow-up visit | The number of participants that complete the protocol defined intervention and follow-up |
| Primary | Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy including medication adherence | Weekly check-in phone calls, 45 Days following treatment initiation (+/- one week), and 3-month follow-up visit | The number of participants that adhere to the medication intervention |
| Primary | Evaluate the safety of 10 mg/day empagliflozin by evaluating medication tolerance | Weekly check-in phone calls, 45 Days following treatment initiation (+/- one week), and 3-month follow-up visit | The number of adverse events related to empagliflozin treatment, including urinary tract infections (UTIs), genital mycotic infections (GMIs), dehydration, hypotension, hypoglycemia, diabetic ketoacidosis, worsening renal function, allergic reactions, and other treatment-emergent adverse events |
| Primary | Evaluate the safety of 10 mg/day empagliflozin by evaluating medication safety and tolerance | Weekly check-in phone calls, 45 Days following treatment initiation (+/- one week), and 3-month follow-up visit | The number of participants requiring discontinuation of empagliflozin due to treatment-related adverse events |
| Secondary | Collect measures of cardiac function, and to assess the variability of these measures to inform sample size calculations and power analyses for future studies. | Baseline, and 3-month follow-up | Collect preliminary measures of cardiac function, including left ventricular ejection fraction (LVEF). LVEF is the percentage of blood pumped out of the left ventricle with each heartbeat. 55-69%: Normal, 45-54%: Mildly reduced, 30-44%: Moderately reduced, \<30%: Severely reduced |
| Secondary | Collect measures of cardiac function and to assess the variability of these measures to inform sample size calculations and power analyses for future studies. | Baseline, and 3-month follow-up | Collect preliminary measures of cardiac function, including cardiac output (CO). CO is the total volume of blood pumped by the heart per minute, measured by cardiovascular magnetic resonance imaging (CMR). |
| Secondary | Collect measures of cardiac function, and to assess the variability of these measures to inform sample size calculations and power analyses for future studies. | Baseline, and 3-month follow-up | Collect preliminary measures of cardiac function, including 6 minute walk distance. The six-minute walk test (6MWT) is a validated, submaximal exercise test that measures the distance a patient can walk on a flat, hard surface in six minutes. The 6MWT evaluates how well the cardiopulmonary, musculoskeletal, and metabolic systems work together during physical activity |
| Secondary | Collect measures inflammatory biomarkers, and circulating ceramides, and to assess the variability of these measures to inform sample size calculations and power analyses for future studies. | Baseline, and 3-month follow-up | Collect measure of inflammatory biomarkers (such as plasma concentrations of CRP, Interleukin 18, and Interleukin 1b) and circulating ceramides (such as plasma concentrations of the detectable ceramides species). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883512
GET https://conductscience.org/api/trials/v1/NCT07883512/registered